4Lok AS, Mcmahon BJ. Chronic hepatitis B. Hepatology, 2007,45: 507-539.
5Zeuzem S, Buti M, Gane E, et al. Baseline parameters predict both early virologic response and longer term outcomes for tlebivudine treated pa- tients with chronic hepatitis B. Hepatology, 2007, 46 (Suppl 1 ) :$681A.
6Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B : sum- mary of a clinical research workshop. Hepatology, 2007, 45: 1056-1075.
7Lok AS, Lai CL, Leung N, et al. Long term safety of lamivudine treat- ment in patients with chronic hepatitis B. Gastroenterology ,2003,125: 1714-1722.
8Lara A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chroni- cally infected patients. Hepatology,2006,44 : 694-702.
9Wang F, Wang H, Shen H, et al. Evolutiong of hepatitis B virus poly- merase mutations in a patient with HBeAg positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nu- cleotide analogues. Clin Ther,2009 ,31:360-366.
10Dienstag, JL, Wei LJ, Xu D, et al. Cross study analysis of the relative ef- ficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig, 2007,27 : 35- 49.
